What's Happening?
Verastem Oncology has announced promising two-year median follow-up data from the Phase 2 RAMP 201 clinical trial evaluating the combination therapy of avutometinib capsules and defactinib tablets in patients with recurrent low-grade serous ovarian cancer
(LGSOC). The trial demonstrated sustained clinical benefits, with 52% of patients with a KRAS mutation and 30% of patients with KRAS wild-type remaining on therapy for over a year. The combination therapy showed a well-tolerated safety profile, with no new safety signals and a low discontinuation rate due to adverse events. The data was presented at the Society of Gynecologic Oncology 2026 Annual Meeting, reinforcing the therapy's potential as a durable and clinically meaningful option for patients.
Why It's Important?
The positive follow-up data from the RAMP 201 trial highlights the potential of avutometinib and defactinib as a long-term treatment option for patients with recurrent LGSOC, a condition with limited treatment options. The sustained efficacy and manageable safety profile of the combination therapy offer hope for improving patient outcomes and quality of life. The findings may influence treatment protocols and encourage further research into combination therapies for other types of cancer. The success of the trial underscores the importance of targeted therapies in oncology, particularly for cancers driven by specific genetic mutations.
What's Next?
Verastem Oncology is conducting a Phase 3 confirmatory trial to further evaluate the combination therapy's efficacy and safety compared to standard chemotherapy or hormonal therapy. The results of this trial will be crucial for securing continued FDA approval and potentially expanding the therapy's use in other cancer types. Researchers will continue to monitor long-term outcomes and explore the potential for combination therapies in first-line treatment settings. The ongoing research may lead to new insights into the mechanisms of drug resistance and inform the development of more effective treatment strategies.
